Harvard Apparatus Regenerative Technology (HRGN) investor relations material

Executive summary

• Clinical-stage biotech focused on regenerative medicine for GI disorders and consumer health products, with two operating segments: Regenerative Biotech (US) and Consumer Health Products (Asia).

• Product revenue growth driven by expanded distribution and new product launches in Consumer Health Products, notably CoQ-10 and sleep aid gummies.

• Ongoing Phase 1 clinical trial for esophageal implant faces recruitment delays due to stringent eligibility and logistical challenges.

• Company continues to incur operating losses and negative cash flows, with substantial doubt about ability to continue as a going concern.

Financial highlights

• Product revenue for Q2 2026 was $414,000, up 31% year-over-year; six-month revenue was $640,000, up 77%.

• Operating loss for Q2 2026 was $1.7 million, a 7% improvement year-over-year; six-month operating loss was $3.3 million.

• Net loss for Q2 2026 was $1.7 million ($0.10 per share); six-month net loss was $3.3 million ($0.19 per share).

• Cash and cash equivalents at June 30, 2026 were $351,000, with an accumulated deficit of $109.9 million.

• Net cash used in operating activities for the first half of 2026 was $1.5 million; $500,000 raised via related-party bridge loans.

Outlook and guidance

• Cash on hand and recent advances expected to fund operations into Q4 2026; additional capital required to continue beyond that.

• Actively seeking further financing through equity, debt, grants, or strategic collaborations.

• If unable to raise capital in Q3 2026, may be forced to curtail or cease operations.